Shots:

• The P-I/II dose expansion studies evaluate the safety & preliminary anti-tumor efficacy of VT1021 as monothx. in patients with dose-escalation & expansion cohorts with rGBM & PC. The results of both studies are expected in Q4’21
• In the rGBM expansion cohort- the therapy showed a complete tumor regression & PR- patients remain on trial for ~9mos. & continue to receive therapy in an open-label extension study. In PC expansion cohort- reduction in tumor with measurable disease & able to reprogram tumor immune microenvironment from immune-suppressive to immune-responsive
• The company plans to initiate a P-II/III study of VT1021 for newly diagnosed & recurrent GBM patients at the end of 2021

| Ref: Vigeo | Image: Reuter